SS-31

Overview

SS-31 (elamipretide, also designated Bendavia and MTP-131) is a synthetic cell-permeable tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2 that selectively concentrates approximately 5,000-fold within the inner mitochondrial membrane (IMM) driven by the large electrochemical potential gradient across the IMM. At the molecular level, SS-31 binds selectively to cardiolipin, a unique bis-phosphatidylglycerol phospholipid found exclusively in the IMM that is essential for the structural organization of electron transport chain (ETC) supercomplexes and the activity of cytochrome c oxidase (Complex IV) and ATP synthase (Complex V). Published peer-reviewed research demonstrates that cardiolipin undergoes peroxidative damage with aging and in metabolic disease, leading to ETC disorganization, electron leak, excessive reactive oxygen species (ROS) production, and impaired ATP synthesis — a vicious cycle of mitochondrial decline. By stabilizing cardiolipin's interaction with ETC complexes, SS-31 restores supercomplex assembly, improves electron transfer efficiency, reduces ROS generation at the source rather than scavenging it downstream, and enhances ATP output. What distinguishes SS-31 from conventional antioxidants is its targeted accumulation at the precise mitochondrial site of ROS generation, addressing the cause rather than the consequence of mitochondrial oxidative stress. SS-31 has advanced into human clinical trials for Barth syndrome (a cardiolipin remodeling disorder), primary mitochondrial myopathy, heart failure with preserved ejection fraction, and age-related macular degeneration, making it one of the most clinically advanced mitochondria-targeted peptide therapeutics. Current investigation continues across cardiac, renal, ophthalmic, skeletal muscle, and neurological applications.

Research Applications

Frequently Asked Questions